December 2011. Volume 7. Number 4

New data support the lack of cardiovascular risk of psychoactive drugs used for attention-deficit/hyperactivity disorder

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-904.
Reviewers: Aparicio Rodrigo M1, González de Dios J2.
1Centro de Salud Entreví­as. Área 1. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: María Aparicio Rodrigo. Email: maparicio@salud.madrid.org
Reception date: 18/11/2011
Acceptance date: 21/11/2011
Publication date: 23/11/2011

Abstract

Authors’ conclusions: there is no evidence that current use of an attention-deficit hyperactivity disorder drug was associated with an increased risk of serious cardiovascular events.

Reviewers’ commentary: this new study, with a higher sample than the previous ones, continues to support their findings on the lack of cardiovascular effects of psychoactive drugs used for patients with attention-deficit/hyperactivity disorder.

How to cite this article

Aparicio Rodrigo M, González de Dios J. Nuevos datos apoyan la falta de riesgo cardiovascular de los psicofármacos empleados para el trastorno por déficit de atención e hiperactividad. Evid Pediatr. 2011;7:81.

AVC | Critically appraised articles

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-904.
Reviewers: Aparicio Rodrigo M1, González de Dios J2.
1Centro de Salud Entreví­as. Área 1. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: María Aparicio Rodrigo. Email: maparicio@salud.madrid.org
Reception date: 18/11/2011
Acceptance date: 21/11/2011
Publication date: 23/11/2011

How to cite this article

Aparicio Rodrigo M, González de Dios J. Nuevos datos apoyan la falta de riesgo cardiovascular de los psicofármacos empleados para el trastorno por déficit de atención e hiperactividad. Evid Pediatr. 2011;7:81.

References

  1. Aparicio Rodrigo M, González de Dios J, Ramos Lizana J. Se puede tratar el déficit de atención con hiperactividad sin hacer un electrocardiograma. Evid Pediatr. 2011;7:80.
  2. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP et al. Cardiovascular events and death in children exposed and unexposed to ADHD Agents. Pediatrics. 2011;127:1102-10.
  3. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M et al. Sudden death and use of stimulant medication in youths. Am J Psychiatry. 2009;166:992-1001.
  4. Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD). En: FDA U.S. Food and Drug Administration [en línea] [fecha de consulta: 10-VII-2011]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165858.htm
23/11/2011

Linked Comment